A single day of treatment with an inhaled synthetic formulation of mebufotenin (GH001) significantly reduced depression symptoms in adults with treatment-resistant depression compared to placebo. In a randomized, double-blind trial of 81 patients, those receiving up to three escalating doses of GH001 showed an average 15.5-point greater improvement on the Montgomery-Åsberg Depression Rating Scale by day 8 than those on placebo. Remission rates were 57.5% for GH001 and 0% for placebo. No severe or serious adverse events occurred. The findings suggest GH001 may be a rapid-acting, well-tolerated treatment option for treatment-resistant depression.
Mindfulness-based cognitive therapy (MBCT) delivered in primary care can effectively reduce depressive symptoms, especially for those with severe depression. Among 433 individuals, 60% had moderate-to-severe depression before treatment. After MBCT, 35.6% of the severely depressed group recovered. Only 2.1 to 2.7% deteriorated. Higher pre-treatment depression severity, more sessions attended, and younger age were linked to greater symptom improvement, while personality traits were not. MBCT appears safe and effective in real-world primary care settings.